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Background: Rubinstein-Taybi syndrome (RSTS; OMIM 180849) is a rare autosomal dominant developmental disorder 
with an estimated prevalence of  one case per 125,000 live births. RSTS is characterized by typical face, broad thumbs and 
halluces, short stature, and intellectual disability. Facial dysmorphy is characteristic with microcephaly, low frontal hairline, 
arched eyebrows, long eyelashes, convex profile of  nose, narrow palate, and micrognathia. RSTS is mainly due to mutations 
or microdeletions of  the CREBBP gene (about 60%) and more rarely of  the EP300 gene (8%).
Objective: Clinical description and identification of  mutations of  patients with Rubinstein Taybi syndrome
Methods: PCR and direct sequencing of  CREBBP gene.
Results: We report here, the clinical and molecular data of  a series of  six Moroccan patients with a phenotype of  RSTS. The 
molecular study of  the major gene CREBBP (by Sanger Sequencing followed by CGH array, if  sequence normal) revealed 
point mutations in five patients. For the sixth patient, CGH array revealed a microdeletion carrying the CREBBP gene. 
Through this work, we emphasize the importance of  clinical expertise in the diagnosis, management and genetic counseling 
in Rubinstein Taybi syndrome.
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Introduction
Rubinstein-Taybi syndrome (RSTS; OMIM 180849, 
RSTS2; OMIM 613684) is a rare autosomal dominant 
genetic disease, with a prevalence estimated at one case 
per 125000 live births1. It is characterized by facial dys-
morphy, microcephaly, broad thumbs and first toes, 
postnatal growth retardation, and intellectual disability.
Facial dysmorphy is characterized by low frontal hair-
line, arched eyebrows, downslanting palpebral fissures, 
hypertelorism, long eyelashes, a beaked nose, low set 
ears, arched palate, micrognathia, dental anomalies 
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(overcrowding of  teeth), and atypical smile (“grimac-
ing”). Typically, hands present a big thumb and a  clino-
dactyly of  the fifth finger. Other skeletal anomalies are 
described, including ligamentous laxity, vertebral anom-
alies, and abducted thumbs2,3. Other features may in-
clude multiple malformations including cardiac, ocular, 
genitourinary, digestive, and/or cutaneous disorders. 
Constipation often presents throughout life and some 
patients are overweight in late childhood or early puber-
ty. Tendency of  overweight or obesity was reported in 
RSTS patients, especially during adolescence, needing 
specific growth charts for appropriate assessment of  the 
growth4. The patients also have an increased risk of  de-
veloping benign tumors (pilomatricomas) or malignant 
tumors (brain tumors, acute leukemias, lymphomas)2,3,5. 
RSTS patients have mild intellectual disability6,7,8. Pa-
tients have usually friendly and sociable characteristics. 
However, in some patients motor stereotypies, short 
attention span, and poor coordination have ben de-
scribed9. Additionally, some RSTS had mood swings 
and obsessive compulsive behavior especially in adult-
hood6,10. More than 90% of  RSTS patients survive to 
adulthood, but their healthcare is difficult, due to ab-
sence of  standardized specific guidelines10.
Mutations in two highly conserved genes have been 
implicated in the etiology of  RSTS. These are cAMP 
response element-binding protein (CREB) binding pro-
tein (CREBBP; NM_600140) localized at 16p13.3 and 
EA1-associated protein p300 (EP300; NM_602700) lo-
calized at 22q13 mutated respectively in about 60% and 
8% of  cases11,12. More than half  of  patients with RST 
have mutations in CREBBP gene. CREBBP and EP300 
are two ubiquitous expression genes with a major role 
in chromatin remodeling by acetylation of  histones, a 
mechanism particularly involved in neuronal plasticity 
and cognition13. There is no clear genotype phenotype 
correlation14. A few familial cases with germline and so-
matic mosaicism have been reported15,16,17. We report 




Six patients with a facial dysmorphy and malformations 
presented to our Department of  Medical Genetics. All 
the patients were examined by clinical geneticists and a 
suspicion of  clinical diagnosis of  RSTS was evoked for 
these patients. Informed consent was obtained for all 
the patients and their parents, and the study was per-
formed with approval of  the regional ethics committee 
at the National Institute of  Health, Rabat. The Genom-
ic DNA from the patients and their parents, when avail-
able, was isolated from peripheral blood according to 
the standard procedures. The Clinical data of  the six 
patients is summarized in Table 1.
Patient 1 was the fifth child of  healthy non consan-
guineous parents. He had no particular family history. 
The patient had normal gestation and delivery. He was 
followed for congenital heart defect. He had psycho-
motor delay. At last clinical examination at two years, 
he had hirsutism, synophris, convex nasal bridge, ret-
rognathism, broad thumbs and halluces, and bilateral 
crytorchidism.
Patient 2 was the second child of  healthy non consan-
guineous parents. There was no family history of  mal-
formations or intellectual disability. The birth weight 
was 2300 g. He had psychomotor delay and an impor-
tant speech delay, with little spoken language. At last 
clinical examination at six years, he had high arched 
broad eyebrows. He had pulmonary stenosis and mi-
cropenis. He had delayed bone age, and his karyotype 
was normal 46,XY.
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Patient 3 was the first child born to healthy non con-
sanguineous parents. The gestation and delivery were 
without any problem. The girl had psychomotor delay. 
At last clinical examination at nine years, she had typical 
facies of  RSTS with low frontal hairline, arched eye-
brows, long eyelashes, downslanting palpebral fissures, 
columella below alae nasi, a highly arched palate, hir-
sutism, and broad thumbs and halluces.
Patient 4 was the fifth child of  healthy non consanguin-
eous parents. The boy was born at 39 weeks of  gesta-
tion after a normal pregnancy. In neonatal period, he 
had hypotonia. He had psychomotor delay and speech 
delay. At last clinical examination at 9 years, he had low 
fontal hairline, arched eyebrows, long eyelashes, downs-
lanting palpebral fissures, hirsutism, clinodactyly of  
fifth finger, bifid tongue, broad thumbs with radial an-
gulation, broad halluces and pectus excavatum. He had 





Table 1: Clinical and molecular findings of the six patients with Rubinstein Taybi Syndrome 
 
Patients Patient 1 Patient 2 Patient 3 Patient 4 
 
Patient 5 Patient 6 
Age at 
diagnosis 
1 year 5 years 9 years 8 years 6 years 3 years 








+ + + + + + 
Intellectual 
disability 
+ + + + + + 
Speech delay + + + + + + 
Low anterior 
hairline 
- - + + + + 
High arched 
ayebrows 
+ + + + + + 
Broad 
ayebrows 
+ + + + + + 
Long 
eyelashes 




+ + + + + + 
Beaked nose + + + + + + 
‘grimacing 
smile’,  
+ + + + - - 
Low set ears + + + + + + 
Hisrsutism + - + + + + 
Micrognathia - - + + + + 
Broad thumbs + - + + + + 
Angulated 
Thumbs 
- + + + - + 
Broad halluces + - + + + + 
Seizures - - - - - - 
Urogenital 
malformation 




+ + - - - + 























Deletion of a 
100 kb 
including the 























Inheritance De novo De novo De novo De novo De novo De novo 
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Patient 5 was the third child of  healthy parents. He 
had psychomotor delay. At last clinical examination at 
6 years, he had hirsutism, typical facies of  RSTS, with 
broad thumbs and halluces.
Patient 6 was the only child of  non consanguineous 
parents. The gestation and delivery were without any 
problem. He had psychomotor delay, and speech de-
lay. At last clinical examination at four years, he had 
short neck, strabism, downslanting palpebral fissures, 
convexed nose, low set ears, high arched palate, broad 
thumbs and halluces, and cryptorchidism. He was fol-
lowed for congenital heart defect (ventricular and atrial 
septum defects). He had also feeding difficulties, recur-
rent pulmonary infections. His karyotype was normal 
46,XY.
The clinical phenotypes of  the patients are summarized 
in Table 1. The patients displayed a classic RSTS phe-
notype with characteristic facial features, broad thumbs, 




Informed consent was obtained for all patients and par-
ents. Polymerase chain reaction (PCR) amplification, 
followed by direct sequencing of  the coding sequence 
and the corresponding exon intron boundaries of  
CREBBP gene (GRCh38:CM000678.2). Sequencing of  
the coding regions was performed using Big Dye Ter-
minator cycle sequencing kit 3.1 (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s stand-
ard protocol and sequenced on an ABI genetic analyzer.
Search for gene dosage anomaly by targeted array Com-
parative Genome Hybridization (CGH): CREBBP and 
EP300 genes and the genomic regions of  the bands 
16p13.3 and 22q13.2 were studied using a custom high 
resolution chip on 60K Custom oligonucleotide slides 
(Agilent Technologies, Courtabœuf, France). The aver-
age distance between two oligonucleotides is 100 bp in 
the genes of  interest and a region of  50 kb on either 
side of  these genes. Following the routine testing pro-
cedure, array comparative genomic hybridization was 
performed with the patient's DNA (Cyanin 5) against 
a control DNA (Cyanin 3) and analyzed by Agilent Cy-
toGenomics 3.0.1.1 software.
Gene dosage anomaly was confirmed using semi Quan-




"Five patients had causal point mutations in the CREB-
BP gene (NM_004380), comprising three nonsense 
mutations, one missense mutation, and one splice mu-
tation. All variants were classified as Pathogenic or 
Likely Pathogenic according to the American College 
of  Medical Genetics (ACMG) guidelines for classifica-
tion of  variants18. None of  the variants were found in 
123,136 exomes and 15,496 genomes from the Genome 
Aggregation Database (gnomAD, accessed March 
2020, ACMG criterion PM2)19. Furthermore, all the 
mutations were found to be de novo after testing of  
both parents (ACMG criterion PS2). Three mutations 
were nonsense (ACMG criterion PVS1): c.3160G>T 
(p.E1054X), c.6169C˃T (p.Q2057X), c.4350C>A 
(p.Y1450X) one splice site mutation (ACMG criteri-
on PVS1): c.3982+5G>A, and one missense mutation 
c.3609G>C (p.K1203N).
For the sixth patient, a heterozygous mosaic dele-
tion was identified at 16p13.3 with a minimum size 
of  97,6 kb (hg19) and a maximum size of  100 kb: ar-
r[GRCh37]16p13.3(3708920- 3806511) x1. This dele-
tion includes exons 20 to 31 of  the CREBBP gene, and 
was expected to disrupt gene function (ACMG crite-
rion PVS1). This deletion also includes the intergenic 
region and the entire TRAP1 gene (Figure 1). The rate 
of  mosaicism has been estimated between 35 and 50% 
in leukocytes. All molecular findings of  the six patients 
are summarized in table 1."
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    Figure 1: Custom array Comparative Genomic Hybridization (CGH). 
Targeted analysis at 16p13.3 showing the heterozygous deletion including the 3’end of CREBBP, 
the intergenic region and TRAP1 (red bar). Gene locations are indicated  by grey bars. 
Gene view, Agilent Cytogenomics software V3, DLRS: 0,17, algorithm: ADM 2.6. Horizontal: 
log2ratio values (homogeneous deletion: -1), vertical: distance in megabases (Mb). 
The mosaic rate was estimated between 35 and 50% by comparing the mean deviation of 
all deleted probes (red rectangle) to the log2ratio values of non deleted probes (vertical black bar). 
Discussion
Rubinstein-Taybi syndrome (RSTS) is a rare genetic syn-
drome and was first described in 19635. Its incidence 
is about 1 in 100,000 to 125,000 live births. Clinically, 
RSTS is characterized by postnatal intellectual disability, 
growth delay, microcephaly, dysmorphic facial features, 
and broad thumbs and halluces20,21. Mutations of  the 
CREBBP gene are identified in 50-70% of  RSTS pa-
tients, while mutations in the EP300 gene have been 
reported in 5-8% patients 12,22,23,24,25. The CREBBP and 
EP300 genes are ubiquitously expressed and are highly-
omologous. CREBBP gene comprises 31 exons, encod-
ing 2442 amino acid CREB-binding protein, whereas 
EP300 consists of  2415 amino acids26. CREBBP gene is 
a co-activator in cyclic-AMP-regulated gene expression. 
This gene is highly conserved, with 95% homology be-
tween human and mouse27,28. CREBBP has an impor-
tant role in cell growth and development especially by 
regulating the transcriptional process. Since CREBBP is 
highly conserved, a mutation or a large deletion is likely 
to cause the full RSTS phenotype.
No evident genotype-phenotype correlations have been 
identified in RSTS. However, a lethal phenotype was re-
ported in three patients with contiguous gene deletions 
including CREBBP gene29. Mosaic microdeletions of  
CREBBP have been recently reported with less severe 
involvement30. Milder RSTS phenotype has been re-
ported in patients with missense mutations7. Seizures 
were reported to be more often frequent in RSTS pa-
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tients with CREBBP mutations14. RSTS phenotype 
such as growth retardation and risk of  seizures seems 
to be modified by CREBBP mutation14.
RSTS is mostly sporadic, and only a rare familial RSTS 
cases have been reported to date15,16,17. The recurrence 
risk of  RSTS is low, but a prenatal diagnosis of  RSTS 
should be proposed to parents due to gonadal mosai-
cism risk. Somatic mosacism, was reported in an unaf-
fected father of  a boy with RSTS and in a mildly affected 
father of  three children with RSTS16,17. The monitoring 
of  RSTS patients should include cardiac evaluation, die-
tary monitoring, and ophthalmologic evaluation24. With 
the emergence of  Next Generation Sequencing, clinical 
spectrum of  RSTS patients has widened. RSTS patients 
with EP300 mutations had less marked facial signs, and 
better cognitive development12. Menke et al., reported 
11 patients with a de novo missense mutation in exons 
30 and 31 of  CREBBP gene, but without RSTS phe-
notype, but 31.  This new condition was then known as 
Menke-Hennekam syndrome (MIM618332).
RSTS patients are more at risk for tumors especially 
medulloblastoma; diffuse large-cell B-cell lymphoma; 
breast cancer; non-small cell lung carcinoma;  and colon 
carcinoma. No clear genotype–phenotype correlation 
became evident32.
In our cohort of  six patients with typically clinical 
features of  RSTS, five were found having mutations 
of  CREBBP gene, and the patient 6 had a microde-
letion found by CGH array, including exons 20 to 31 
of  CREBBP gene, with a mosaicism estimated between 
35% and 50%.  The six variants in CREBBP gene were 
not reported previously in the literature in other Ru-
binstein-Taybi patients.The last patient had a typical fa-
cial dysmorphy of  RSTS, and a moderate intellectual 
disability due probably to the mosaicism. All patients 
showed a phenotype of  RSTS including broad thumbs 
and big toes, but facial dysmorphy was not present in 
all patients. The phenotype of  patient 2 was atypical 
from the classical RSTS phenotype, especially the pro-
nounced speech delay, the distinctive nose, had some 
resemblance with floating Harbor syndrome. This pa-
tient didn’t have broad thumbs or big toes, and nor hir-
sutism. These atypical features were reported in some 
RSTS patients with nonsense CREBBP mutations33,34. 
We here report the CREBBP mutation spectrum in a 
series of  six Moroccan patients with a clinical diagnosis 
of  RSTS. Our results confirm that mutations in CREB-
BP are the major cause of  RSTS.
 
Conclusion
Most cases of  RSTS are sporadic. Familial forms are ex-
tremely rare. This is the first Moroccan cohort, relating 
the clinical and molecular findings. This will allow us to 
provide adequate genetic counseling to the families, and 
to manage adequately the patients.  
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-  PCR: Polymerase chain reaction.
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